Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Zhao

Showing results (421-430 of 462) with videos related to

Pageof 47
Sort By:
American Journal of Physiology. Renal Physiology|August 30, 2013
CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin miceTimothy Sullivan, Zhenhua Miao, Daniel J Dairaghi, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 28, 2017
[Prediction of outcome in acute myeloid leukemia by measurement of WT1 expression as a basic marker of minimal residual disease]N Zhao, H Wei, Y Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Chemical Science|February 3, 2015
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition EnhancersF F Wagner, Y-L Zhang, D M Fass, et al.
British Journal of Cancer|June 28, 2012
Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancerN Zhao, M-K Ang, X-Y Yin, et al.
Plos One|June 7, 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunityKathleen M C Sullivan, Marta Vilalta, Linda S Ertl, et al.
European Journal of Clinical Nutrition|January 29, 2015
Folic acid supplementation and dietary folate intake, and risk of preeclampsiaY Wang, N Zhao, J Qiu, et al.
Physical Review Letters|May 27, 2014
New edge coherent mode providing continuous transport in long-pulse H-mode plasmasH Q Wang, G S Xu, B N Wan, et al.
Nature|January 15, 2025
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancerMasataka Amisaki, Abderezak Zebboudj, Hiroshi Yano, et al.
Nature|November 14, 2017
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancerVinod P Balachandran, Marta Łuksza, Julia N Zhao, et al.
Pageof 47

Showing results (421-430 of 462) with videos related to

Sort By:
Pageof 47
American Journal of Physiology. Renal Physiology|August 30, 2013
CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin miceTimothy Sullivan, Zhenhua Miao, Daniel J Dairaghi, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|September 28, 2017
[Prediction of outcome in acute myeloid leukemia by measurement of WT1 expression as a basic marker of minimal residual disease]N Zhao, H Wei, Y Wang, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 2, 2012
Characterization of CCX140-B, an orally bioavailable antagonist of the CCR2 chemokine receptor, for the treatment of type 2 diabetes and associated complicationsTimothy J Sullivan, Daniel J Dairaghi, Antoni Krasinski, et al.
Chemical Science|February 3, 2015
Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition EnhancersF F Wagner, Y-L Zhang, D M Fass, et al.
British Journal of Cancer|June 28, 2012
Different cellular p16(INK4a) localisation may signal different survival outcomes in head and neck cancerN Zhao, M-K Ang, X-Y Yin, et al.
Plos One|June 7, 2023
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunityKathleen M C Sullivan, Marta Vilalta, Linda S Ertl, et al.
European Journal of Clinical Nutrition|January 29, 2015
Folic acid supplementation and dietary folate intake, and risk of preeclampsiaY Wang, N Zhao, J Qiu, et al.
Physical Review Letters|May 27, 2014
New edge coherent mode providing continuous transport in long-pulse H-mode plasmasH Q Wang, G S Xu, B N Wan, et al.
Nature|January 15, 2025
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancerMasataka Amisaki, Abderezak Zebboudj, Hiroshi Yano, et al.
Nature|November 14, 2017
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancerVinod P Balachandran, Marta Łuksza, Julia N Zhao, et al.
Pageof 47